Abstract
In recent years, many pharmaceutical companies have increasingly focused on optimising clinical development programmes not only to the demands of the regulators, but also to health technology assessment (HTA) bodies (HTABs), and payers. Consequently, there has been an increase in scientific advice processes involving HTABs and regulatory bodies. The objective of this study was to review scientific advice processes involving HTABs in the United Kingdom (UK), France, and Germany as well as the parallel EMA/EUnetHTA21 joint scientific consultation (JSC) process and evaluate similarities and differences between these.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
